Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Vanderbilt University Medical Center
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03486223CT.gov Soluble Epoxide Hydrolase Inhibition and Insulin Resistance | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endocrine System Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gsk-2256294A (this asset) | Vanderbilt University Medical Center | P2 | B · 57 |
| Human Chorionic Gonadotropin | Merck KGaA, Darmstadt, Germany | P3 | BB |
| Testosterone Undecylate | Craig Hospital | P4 | BB |
| Msj-0011 | Merck KGaA, Darmstadt, Germany | P3 | BB |
| Follitropin Alfa | Merck KGaA, Darmstadt, Germany | P3 | BB |
| Irinotecan | Xiaoxiang Chen | P2 | BB |
| Metformin | Assiut University | P2 | B |
| Usistapide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P2 | B |
| Hydrocortisone | Neurocrine UK Limited | P2 | B |
+19 more in the Endocrine System Disorder cohort
Other indications for Gsk-2256294A
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diabetes Mellitus | — | P2 | B · 57 |
| Glucose Metabolism Disease | — | P2 | B · 57 |
| Prediabetes Syndrome | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gsk-2256294A in Endocrine System Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gsk-2256294a-endocrine-system-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →